RT Journal Article
SR Electronic
T1 Remdesivir, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 2021.12.27.474275
DO 10.1101/2021.12.27.474275
A1 Laura Vangeel
A1 Steven De Jonghe
A1 Piet Maes
A1 Bram Slechten
A1 Joren Raymenants
A1 Emmanuel André
A1 Johan Neyts
A1 Dirk Jochmans
YR 2021
UL http://biorxiv.org/content/early/2021/12/28/2021.12.27.474275.abstract
AB The in vitro effect of GS-441524, remdesivir, EIDD-1931, molnupiravir and nirmatrelvir against the various SARS-CoV-2 VOCs, including Omicron, was determined. VeroE6-GFP cells were pre-treated overnight with serial dilutions of the compounds before infection. The number of fluorescent pixels of GFP signal, determined by high-content imaging on day 4 post-infection, was used as read-out, and the EC50 of each compound on a viral isolate of each VOC was calculated. These experiments were performed in the presence of the Pgp-inhibitor CP-100356 in order to limit compound efflux. A SARS-CoV-2 strain grown from the first Belgian patient sample was used as ancestral strain. All the other isolates were obtained from patients in Belgium as well.Our results indicate that GS-441524, remdesivir, EIDD-1931, molnupiravir and nirmatrelvir retain their activity against the VOCs Alpha, Beta, Gamma, Delta and Omicron. This is in accordance with the observation that the target proteins of these antivirals are highly conserved.Competing Interest StatementThe authors have declared no competing interest.